Navigation Links
Primary biliary cirrhosis more severe in African-American and Hispanic patients
Date:9/5/2007

Non-Caucasian patients seeking medical care for primary biliary cirrhosis have more severe liver disease compared to Caucasian patients, a new study has found. The reasons for this disparity are not clear, say the authors. These findings are in the September issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

Primary biliary cirrhosis is an uncommon liver disease that typically afflicts Caucasian women between ages 30 and 60, so there is little data available on how it affects non-Caucasian patients. To shed light on this topic, researchers led by Marion Peters of the University of California in San Francisco set out to examine differences in disease severity among patients of various racial and ethnic groups.

They studied 535 individuals with primary biliary cirrhosis who were screened for possible enrollment into a large, national multicenter clinical trial of ursodeoxycholic acid with or without weekly methotrexate, between April, 1989 and January, 1998. For each patient, they collected demographic information, clinical symptoms, physical findings and laboratory test results. They then examined differences between ethnic groups, genders, and anti-mitochondrial antibody (AMA) status. They also compared the 265 patients who entered the trial to those who did not.

The majority of the patients considered for the trial were Caucasian (86.4 percent). Just 7.9 percent were Hispanic, and 3.9 percent were African-American. Still, the researchers noticed significant differences between Caucasian and non-Caucasian patients. Non-Caucasians appeared to have significantly more severe liver disease than Caucasians, as assessed by history, physical examination and laboratory features, the authors report. Minority patients reported more limitation of activity, more severe itching and more serious complications such as ascites, hepatic encephalopathy and variceal bleeding. Results from the laboratory tests confirmed the disparity in disease severity. Mostly as a result of their poorer health conditions, a significantly smaller proportion of non-Caucasian patients were enrolled in the trialjust 23.2 percent compared to 53.5 percent of Caucasians.

The reasons for the health disparities are unknown, since patients in both groups were of similar age and had the disease for similar lengths of time. It is not clear whether these patients have more rapid disease, less access to care early in their disease, misdiagnoses due to inadequate testing, absence of liver biopsies or presence of comorbidities which may have lead to delay in treatment, the authors report.

To begin to address the disparity, they suggest, primary biliary cirrhosis should be considered as the diagnosis in cholestatic liver disease in all ethnic populations.

While the disease does predominantly affect Caucasian women, this study revealed a significant number of racial minority patients, and disturbing evidence of inexplicably more advanced disease.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. Is caries in primary and permanent tooth related?
3. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
4. Shortage Of Funds In Primary Care Trust In UK
5. What Will Primary Care Look Like In England by 2015?
6. Primary Health Care MoU Signed on the Sidelines of the PBD
7. Primary Care centers to provide out patient treatment
8. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
9. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
10. Gene That Causes Metastasis of the Primary Tumor, Identified
11. IMA To Train Doctors In Primary Treatment Of HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... ... in the Orthodontics and Clear Aligner clinical and commercial support services market) has ... of Dentistry (PGSD) in Sydney, Australia. , The PGSD is the first ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... In just ... Brain Booster has already been receiving positive feedback from customers trying the product for ... , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A ... is the creation of published author, Bill Miller. Bill Miller has a ... more than a decade of addiction to prescription drugs. He has a ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology: